
The $100 Billion Illusion - Why Data, Not Hype, Will Drive AI ROI
It's tempting to believe we've entered the golden age of artificial intelligence. Headlines tout a $100 billion generative AI market by 2026. CEOs mention 'AI' on nearly every earnings call. Consultants pitch productivity revolutions via PowerPoint.
But beneath the surface, a less convenient reality is setting in: for most companies, GenAI is still an expensive experiment—not a source of revenue.
Stephen Klein, CEO, Curiouser.AI, asks, 'Are we using GenAI to solve real problems, or just optimizing slide decks?' Klien is bullish on GenAI in the long run but states 'the near-term business model isn't intelligence. It's fear and influence and a false sense of trust.'
As Klein's remarks suggest, the promise of AI is being eclipsed by performative adoption. His take cuts through the hype with equal parts technical fluency and commercial realism.
Klein isn't alone. As outlined in a recent article from this column—AI Beyond Platforms - How Data Will Unlock New Value In 2025,—one of the most overlooked truths of the current AI cycle is simple: the platform isn't the value. The data is.
The $100 Billion Mirage
Microsoft's claim of a $3.70 return for every $1 spent on GenAI, cited in a white paper it commissioned, lacked any external validation. No Fortune 500 case studies were included.
Meanwhile, AI darlings like OpenAI and Anthropic are running massive deficits. CNBC reports that OpenAI lost $5 billion in 2024, with ChatGPT alone costing an estimated $700,000 per day to operate. Anthropic, according to The Information, burned through $2.7 billion in 2024.
These companies aren't profitable. They're surviving on subsidies—from investors, partners, and strategic alliances.
Consultants and Cohorts: Selling the AI Dream
Klein paints a vivid picture of today's AI marketplace: GPT-powered webinars, $2,000 cohort programs, and 100-slide decks promising to "future-proof" organizations. Klein says, 'This isn't innovation. It's monetized anxiety.' Companies aren't buying transformation—they're buying the appearance of AI readiness.
Take Accenture, which reportedly earned $900 million in GenAI revenue last year, with $3 billion in bookings. But most of that came from consulting—not from clients deploying AI at scale. According to Accenture CEO, Julie Sweet, most of Accenture's clients are in 'experimental mode' with generative AI. Their focus, she said, is on cloud, data, and application modernization.
Where the Money Actually Is: Human-Centered Data
So, where's the real return? It starts with data—specifically, high-quality, forward-looking, zero-party data.
Unlike scraped or synthetic alternatives, real people voluntarily provide zero-party data. It includes behavioral intent, psychographics, motivations, and—critically—future spending plans. These inputs are foundational for models that aim to predict, not just summarize. Here are two examples:
3 Quarter ahead forecasts for CVS Revenues
XTech-MarchCPI Forecast
The takeaway? Many failed GenAI initiatives didn't collapse because of weak models. They failed because they were built on bad data.
As Klein argues, AI should augment human intelligence—not just mimic or automate language.
The Overlooked Reality: A Data Gap, Not a Tech Gap
Klein's critique and the findings in AI Beyond Platforms converge on a core truth: what's holding back AI isn't processing power or better algorithms. It's irrelevant, outdated, or low-signal data.
The excitement around GenAI is real. But so is the gap between experimentation and enterprise-scale impact. Demos dazzle. ROI disappoints.
Unless organizations fuel their models with reliable, representative, and behaviorally rich data, they'll fall into the trap.
From Illusion to Impact: The Path Forward
There is real money to be made with AI—but it won't come from bigger models or louder marketing. It will come from solving real problems with clean, context-rich, human-anchored data.
As the GenAI boom rolls on, the biggest winners won't be those chasing the next model release. They'll be the ones starting with the right data.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Why Casella Waste Systems Stock Flopped on Friday
Key Points The company's bottom-line miss in its second quarter was striking. That was compounded by a guidance reduction for full-year profitability. 10 stocks we like better than Casella Waste Systems › Solid waste and recycling management company Casella Waste Systems (NASDAQ: CWST) was surely eager to start its weekend. On Friday, the company published quarterly results that were a dud with investors, who sent its share price down by more than 5%. That was more deeply in the red than the S&P 500 index's 1.6% dive. One big whiff Much of this was because of a fairly wide bottom-line miss in Casella's second quarter, the results of which were published after market close Thursday. In the quarter, Casella booked revenue of over $465 million. So far, so good, as this was more than 23% higher than in the same quarter of 2024. Further down the profit and loss statement, however, the company revealed that its generally accepted accounting principles (GAAP) net income fell to $5.2 million ($0.08 per share) from the year-ago profit of slightly over $7 million. That drop was discouraging enough, but it was exacerbated by the fact that analysts were expecting far better from the company. On average, they were modeling $0.33 per share for bottom-line profitability, although they underestimated revenue with a collective $454 million projection. Acquisitions played a role in Casella's top-line growth, as the company completed six buyouts across the first half of this year. Management also said higher landfill volumes were a catalyst. Notable guidance revisions Outside of the bottom-line miss, Casella's change in guidance was dismaying for investors. Although it raised its outlook for full-year 2025 revenue -- $1.82 billion to $1.84 billion from just under $1.78 billion to a bit over $1.8 billion -- it cut that for profitability. The company now believes its GAAP net income will land at $8 million to $18 million; the previous guidance called for $10 million to $25 million. Should you buy stock in Casella Waste Systems right now? Before you buy stock in Casella Waste Systems, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Casella Waste Systems wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Casella Waste Systems Stock Flopped on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Why Novo Nordisk Stock Bumped Higher on Friday
Key Points The Federal government might boost its support of weight-loss drugs soon. According to a media report, it's contemplating a five-year, experimental program that would subsidize their costs for qualifying patients. 10 stocks we like better than Novo Nordisk › Unexpected news of a potential support program from the federal government boosted the share prices of weight-loss drug developers on Friday. The poster boy for that still rather small group, Wegovy/Ozempic maker Novo Nordisk (NYSE: NVO), understandably saw a stock price lift that day. It rose by more than 2%, contrasting well with the 1.6% slide of the S&P 500 index. Federal help for obesity drugs? That news came from The Washington Post, which published an article stating that the Trump administration is planning an experimental program that would cover the costs of such medications. Citing documents from the Centers for Medicare and Medicaid Services (CMS) it had obtained, the newspaper said the plan would be implemented by state Medicaid administrations. It would also be utilized by Medicare Part D insurance plans. These entities would be allowed to cover weight-loss drugs for qualifying patients. At the moment, Medicare generally covers such treatments for patients who suffer from type 2 diabetes. Both Novo Nordisk's Wegovy and rival Eli Lilly's Zepbound are essentially versions of predecessor diabetes drugs. Some private insurance plans cover obesity medications. The Post wrote that the experimental program will last for five years. Massive potential impact Novo Nordisk hasn't yet commented on the article, but we can be sure the company is excited about the prospect. Combined, Medicare and Medicaid are immense programs. Even if only a few states are willing to cover weight-loss treatments through them, the company could experience a surge in sales. For the stock's investors, this is a potentially very impactful development well worth monitoring. Should you buy stock in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Novo Nordisk Stock Bumped Higher on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Addus HomeCare (ADUS) Q2 Earnings: What To Expect
Home healthcare provider Addus HomeCare (NASDAQ:ADUS) will be reporting results this Monday afternoon. Here's what you need to know. Addus HomeCare missed analysts' revenue expectations by 0.6% last quarter, reporting revenues of $337.7 million, up 20.3% year on year. It was a mixed quarter for the company, with a narrow beat of analysts' sales volume estimates. Is Addus HomeCare a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Addus HomeCare's revenue to grow 20.8% year on year to $346.5 million, improving from the 10.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.46 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Addus HomeCare has missed Wall Street's revenue estimates three times over the last two years. Looking at Addus HomeCare's peers in the senior health, home health & hospice segment, some have already reported their Q2 results, giving us a hint as to what we can expect. BrightSpring Health Services delivered year-on-year revenue growth of 15.3%, beating analysts' expectations by 5.2%, and Option Care Health reported revenues up 15.4%, topping estimates by 4.6%. Option Care Health traded down 2.7% following the results. Read our full analysis of BrightSpring Health Services's results here and Option Care Health's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the senior health, home health & hospice stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Addus HomeCare is down 5.3% during the same time and is heading into earnings with an average analyst price target of $136.45 (compared to the current share price of $104.74). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data